GENOME EDITING

[scholarly articles]

Human genome editing: Position paper

Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing

Full article here.

Human genome editing: recommendations

Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing

Full article here.

Human genome editing: A framework for governance

WHO Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing

Full article here.

ISSCR: grave omission of age limit for embryo research

Johnston, J., Baylis, F., & Greely, H. (2021). ISSCR: grave omission of age limit for embryo research. Nature 594, 495.

Full article here.

ISSCR guidelines fudge heritable human-genome editing

Baylis, F. (2021). ISSCR guidelines fudge heritable human-genome editing. Nature 594, 333.

Full article here.

Human Germline and Heritable Genome Editing: The Global Policy Landscape

Baylis, F., Darnovsky, M., Hasson, K., and Krahn, T. (2020). Human Germline and Heritable Genome Editing: The Global Policy Landscape. The CRISPR Journal 3(5): 365-377. DOI:10.1089/crispr.2020.0082.

Full article here.

Perspective: Reactions to the National Academies/Royal Society Report on Heritable Human Genome Editing

Baylis, F. (2020). Perspective: Reactions to the National Academies/Royal Society Report on Heritable Human Genome Editing. The CRISPR Journal 3(5): 338. DOI: 10.1089/crispr.2020.29106.man.

Full article here.

To publish or not to publish

Baylis, F. (2020). To publish or not to publish. Nature Biotechnology 38(3), 271. DOI: 10.1038/s41587-020-0435-1.

Full article here.

Geneva statement on heritable human genome editing: The need for course correction

Andorno, R., Baylis, F., Darnovsky, M., Dickenson, D., Haker, H., Hasson, K., et al. (2020). Geneva statement on heritable human genome editing: The need for course correction. Trends in Biotechnology 38(4), 351-354.  DOI: 10.1016/j.tibtech.2019.12.022.

Full article here.

Human genome editing: Our future belongs to all of us

Baylis, F. (2019). Human genome editing: Our future belongs to all of us. Issues in Science and Technology 35(3), 42-44.

Full article here.

Adopt a moratorium on heritable genome editing

Lander, E., Baylis, F., Zhang, F., et al. (2019). Adopt a moratorium on heritable genome editing. Nature 567, 165-168. DOI: 10.1038/d41586-019-00726-5.

Full article here.

Questioning the proposed translational pathway for germline genome editing

Baylis, F. (2019). Questioning the proposed translational pathway for germline genome editing. Nature Human Behaviour 3, 200. DOI: 10.1038/s41562-019-0544-3.

Full article here.

Building capacity for a global genome-editing observatory: Institutional design

Saha, K., Hurlbut, J.B., Jasanoff, S., Ahmed, A., Appiah, A., Bartholet, E., Baylis, F., et al. (2018). Building capacity for a global genome-editing observatory: Institutional design. Trends in Biotechnology 36(8), 741-743.  DOI: 10.1016/j.tibtech.2018.04.008.

Abstract here.

Building capacity for a global genome-editing observatory: Conceptual challenges

Hurlbut, J.B., Jasanoff, S., Saha, K., Ahmed, A., Appiah, A., Bartholet, E., Baylis, F., et al. (2018). Building capacity for a global genome-editing observatory: Conceptual challenges. Trends in Biotechnology 36(7), 639-641. DOI: 10.1016/j.tibtech.2018.04.009.

Abstract here.

‘No’ to lesbian motherhood using human nuclear genome transfer

Baylis, F. (2018). ‘No’ to lesbian motherhood using human nuclear genome transfer. Journal of Medical Ethics 44(12), 865-867.  DOI:10.1136/medethics-2018-104860.

Abstract here.

COUNTERPOINT: The potential harms of human gene editing using CRISPR-Cas9

Baylis, F. (2018). COUNTERPOINT: The potential harms of human gene editing using CRISPR-Cas9. Clinical Chemistry 64(3), 489-491.  DOI: 10.1373/clinchem.2017.278317.

Full article here.

First-in-human phase 1 CRISPR gene editing cancer trials: Are we ready?

Baylis, F., and McLeod, M. (2018). First-in-human phase 1 CRISPR gene editing cancer trials: Are we ready?  Current Gene Therapy 17(4), 309-319. DOI: 10.2174/1566523217666171121165935.

Full article here.

Human nuclear genome transfer (so-called mitochondrial replacement): Clearing the underbrush.

Baylis, F. (2017). Human nuclear genome transfer (so-called mitochondrial replacement): Clearing the underbrush. Bioethics 31(1), 7-19. DOI:10.1111/bioe.12309.

Abstract here.

Human germline genome editing and broad societal consensus

Baylis, F. (2017). Human germline genome editing and broad societal consensus. Nature Human Behaviour 1, 0103. DOI: 10.1038/s41562-017-0103.

Full article here.

The Council of Europe and the Prohibition on Human Germline Genome Editing

Baylis, F., and Ikemoto, L. (2017). The Council of Europe and the Prohibition on Human Germline Genome Editing. EMBO Reports 18(12), 2084-2085. DOI 10.15252/embr.201745343.

Full article here.

‘Broad societal consensus’ on human germline editing

Baylis, F. (2016). ‘Broad societal consensus’ on human germline editing. Harvard Health Policy Review 15(2), 19-23.

Full article here.

CRISPR-Cas9 system: Opportunities and concerns

Vasiliou, S.K., Diamandis, E.P., Church, G.M, Greely, H.T., Baylis, F., Thompson, C., and Schmitt-Ulms, G. (2016). CRISPR-Cas9 system: Opportunities and concerns. Clinical Chemistry 62(10), 1304-11. DOI: 10.1373/clinchem.2016.263186.

Full article here.